Market Intelligence, Clinical Progress, and High-Purity Reagents for FAAH1 Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FAAH/FAAH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAAH1 Catalytic Domain & Full-Length Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. |
View FAAH Products |
| Gene Delivery | FAAH1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293 Expressed (Native Glycosylation). |
View FAAH Products |
| Benchmark Ab | Anti-FAAH (Sequence Verified) Recombinant positive control for Western/ELISA. |
View FAAH Products |
| Validator | FAAH1 siRNA Set For knockdown verification and assay specificity. |
View FAAH Products |
| Related Target | FAAH2 Paralog serine hydrolase; essential for selectivity counter-screening. |
View FAAH2 Products |
| Related Target | MAGL (Monoacylglycerol Lipase) Parallel endocannabinoid pathway; dual inhibitor programs. |
View MAGL Products |
| Related Target | CNR1 (CB1 Receptor) Primary downstream signaling effector for AEA. |
View CNR1 Products |
| Related Target | NAAA (N-acylethanolamine acid amidase) Synergistic NAE degradation enzyme. |
View NAAA Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Serine Hydrolase Off-Target Toxicity | Highly purified homolog proteins (MAGL, ABHD, FAAH2) available with strict sequence verification for counter-screening panels. |
| Membrane Protein Conformation | Lentivirus-mediated stable cell line construction tools to preserve native endoplasmic reticulum localization. |
| Lack of Controls | Anti-FAAH Benchmark Antibodies and validated Lentivirus included. |
| False Positives | Validated siRNA included for specificity and target-validation checks. |
| Cross-Species Evaluation | Human/Mouse/Cyno/Rat FAAH1 ortholog proteins available with >95% purity. |
Live FAAH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FAAH therapeutics has experienced significant setbacks—notably the suspension of several first-generation clinical programs following severe adverse events with early covalent inhibitors (e.g., BIA 10-2474). Despite this, the biological validation of FAAH1 as the primary regulator of anandamide and N-acylethanolamine tone remains intact. Major players such as Pfizer (PF-04457845), Janssen (JNJ-42165279), and Sanofi (SSR-411298) advanced programs into Phase II, but most were discontinued due to efficacy or safety concerns. The next wave of R&D is shifting focus from traditional systemic small molecules to highly selective, peripherally restricted inhibitors, dual FAAH/MAGL modulation, and non-CNS penetrant localized therapies for neuropathic pain, inflammatory bowel disease, and metabolic indications. Activity-based protein profiling (ABPP) and mechanism-based patient stratification are now critical for clinical success.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Systemic) | Pfizer, Janssen, Sanofi (legacy), Bial | Chronic pain, Anxiety, Inflammation | Enzymatic activity & selectivity (Need high-purity FAAH1 catalytic domain; FAAH2/MAGL counter-screen panel) |
| Peripherally Restricted Inhibitor | Multiple Biopharmas | Neuropathic Pain, IBD, Peripheral Inflammatory Pain | Selectivity Assay & Cellular Permeability (Need high-purity enzyme & stable FAAH1-overexpressing cells via Lentivirus) |
| Dual FAAH/MAGL Inhibitor | Emerging Biotechs | Chronic Pain, Neuroinflammation | Hetero-target engagement profiling (Need both FAAH and MAGL recombinant proteins) |
| Gene Therapy / RNAi | Academic / Preclinical | Localized Inflammation, Metabolic Syndrome | Target knockdown verification (Need siRNA and Benchmark Abs) |